BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37855027)

  • 21. The Role of T Cell Immunity in Monoclonal Gammopathy and Multiple Myeloma: From Immunopathogenesis to Novel Therapeutic Approaches.
    Lagreca I; Riva G; Nasillo V; Barozzi P; Castelli I; Basso S; Bettelli F; Giusti D; Cuoghi A; Bresciani P; Messerotti A; Gilioli A; Pioli V; Colasante C; Vallerini D; Paolini A; Maccaferri M; Donatelli F; Forghieri F; Morselli M; Colaci E; Leonardi G; Marasca R; Potenza L; Manfredini R; Tagliafico E; Trenti T; Comoli P; Luppi M
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563634
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma.
    Oliva S; De Paoli L; Ruggeri M; Caltagirone S; Troia R; Oddolo D; D'Agostino M; Gilestro M; Mina R; Saraci E; Margiotta Casaluci G; Genuardi E; Bringhen S; Boccadoro M; Omedé P
    Ann Hematol; 2021 Feb; 100(2):437-443. PubMed ID: 33392702
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Spatiotemporal assessment of immunogenomic heterogeneity in multiple myeloma.
    Merz M; Hu Q; Merz AMA; Wang J; Hutson N; Rondeau C; Celotto K; Belal A; Alberico R; Block AW; Mohammadpour H; Wallace PK; Tario J; Luce J; Glenn ST; Singh P; Samur M; Munshi N; Liu S; McCarthy PL; Wei L; Hillengass J
    Blood Adv; 2023 Mar; 7(5):718-733. PubMed ID: 35868022
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Monoclonal gammopathy of undetermined significance and asymptomatic multiple myelom in the year 2014 ].
    Adam Z; Krejčí M; Pour L; Sevčíková E; Křivanová A; Rehák Z; Koukalová R; Cermáková Z; Vaníček J; Sevčíková S
    Vnitr Lek; 2014 Oct; 60(10):861-79. PubMed ID: 25382009
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating Ki67 positive lymphocytes in multiple myeloma and benign monoclonal gammopathy.
    Miguel-Garcia A; Matutes E; Tarin F; Garcia-Talavera J; Miguel-Sosa A; Carbonell F; Catovsky D
    J Clin Pathol; 1995 Sep; 48(9):835-9. PubMed ID: 7490317
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Alteration of T-Cell Heterogeneity and PD-L1 Colocalization During dMMR Colorectal Cancer Progression Defined by Multiplex Immunohistochemistry.
    Yan H; Li Y; Wang X; Qian J; Xu M; Peng J; Huang D
    Front Oncol; 2022; 12():867658. PubMed ID: 35669431
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treg and Oligoclonal Expansion of Terminal Effector CD8
    Joshua DE; Vuckovic S; Favaloro J; Lau KHA; Yang S; Bryant CE; Gibson J; Ho PJ
    Front Immunol; 2021; 12():620596. PubMed ID: 33708212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High levels of FLT3-ligand in bone marrow and peripheral blood of patients with advanced multiple myeloma.
    Steiner N; Hajek R; Sevcikova S; Borjan B; Jöhrer K; Göbel G; Untergasser G; Gunsilius E
    PLoS One; 2017; 12(7):e0181487. PubMed ID: 28727816
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased exhausted CD8
    Tan J; Chen S; Huang J; Chen Y; Yang L; Wang C; Zhong J; Lu Y; Wang L; Zhu K; Li Y
    Asia Pac J Clin Oncol; 2018 Oct; 14(5):e266-e274. PubMed ID: 29943497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer.
    Jia K; Chen Y; Sun Y; Hu Y; Jiao L; Ma J; Yuan J; Qi C; Li Y; Gong J; Gao J; Zhang X; Li J; Zhang C; Shen L
    BMC Med; 2022 Jul; 20(1):223. PubMed ID: 35811317
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictive Immune Markers for Disease Progression in Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance.
    İşgör İŞ; Toptaş T; Türkoz HK
    Turk J Haematol; 2022 Dec; 39(4):245-253. PubMed ID: 35965418
    [TBL] [Abstract][Full Text] [Related]  

  • 32. T cell repertoire in patients with multiple myeloma and monoclonal gammopathy of undetermined significance: clonal CD8+ T cell expansions are found preferentially in patients with a low tumor burden.
    Halapi E; Werner A; Wahlström J; Osterborg A; Jeddi-Tehrani M; Yi Q; Janson CH; Wigzell H; Grunewald J; Mellstedt H
    Eur J Immunol; 1997 Sep; 27(9):2245-52. PubMed ID: 9341766
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential pattern of CD4+ and CD8+ T-cell immunity to MAGE-A1/A2/A3 in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma.
    Goodyear OC; Pratt G; McLarnon A; Cook M; Piper K; Moss P
    Blood; 2008 Oct; 112(8):3362-72. PubMed ID: 18658027
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MYC protein expression is detected in plasma cell myeloma but not in monoclonal gammopathy of undetermined significance (MGUS).
    Xiao R; Cerny J; Devitt K; Dresser K; Nath R; Ramanathan M; Rodig SJ; Chen BJ; Woda BA; Yu H
    Am J Surg Pathol; 2014 Jun; 38(6):776-83. PubMed ID: 24705315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased activated regulatory T cell subsets and aging Treg-like cells in multiple myeloma and monoclonal gammopathy of undetermined significance: a case control study.
    Wang JN; Cao XX; Zhao AL; Cai H; Wang X; Li J
    Cancer Cell Int; 2018; 18():187. PubMed ID: 30479566
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myeloma.
    Racanelli V; Leone P; Frassanito MA; Brunetti C; Perosa F; Ferrone S; Dammacco F
    Blood; 2010 Feb; 115(6):1185-93. PubMed ID: 20008301
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive Patients.
    Ely S; Forsberg P; Ouansafi I; Rossi A; Modin A; Pearse R; Pekle K; Perry A; Coleman M; Jayabalan D; Di Liberto M; Chen-Kiang S; Niesvizky R; Mark TM
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):825-833. PubMed ID: 29051077
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma.
    Ocqueteau M; Orfao A; Almeida J; Bladé J; González M; García-Sanz R; López-Berges C; Moro MJ; Hernández J; Escribano L; Caballero D; Rozman M; San Miguel JF
    Am J Pathol; 1998 Jun; 152(6):1655-65. PubMed ID: 9626070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis.
    Rajkumar SV; Mesa RA; Fonseca R; Schroeder G; Plevak MF; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Gertz MA; Kyle RA; Russell SJ; Greipp PR
    Clin Cancer Res; 2002 Jul; 8(7):2210-6. PubMed ID: 12114422
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance.
    Kumar S; Rajkumar SV; Kyle RA; Lacy MQ; Dispenzieri A; Fonseca R; Lust JA; Gertz MA; Greipp PR; Witzig TE
    J Clin Oncol; 2005 Aug; 23(24):5668-74. PubMed ID: 16110026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.